• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Vaccitech plc

    2/11/22 10:00:09 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VACC alert in real time by email
    SC 13G 1 g210225sc13g.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. __)*

     

    Vaccitech plc
    (Name of Issuer)
     
    ADS, each representing one ordinary share 
    (Title of Class of Securities)
     
       91864C107  
    (CUSIP Number)
     
     31 December 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    oRule 13d-1(b)

     

    oRule 13d-1(c)

     

    xRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     1 
     

     

    CUSIP No .   91864C107   Page 2 of 4

     

    1

    NAME OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE  PERSONS (ENTITIES ONLY) 

     

     

    Oxford Science Enterprises plc

    No I.R.S. Identification Number

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

    (a) o

    (b) o

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION 

     

     England, United Kingdom
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON
    WITH:

     
    5 SOLE VOTING POWER  8,797,770
    6 SHARED VOTING POWER  0
    7 SOLE DISPOSITIVE POWER  8,797,770
    8 SHARED DISPOSITIVE POWER  0
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
    PERSON
     8,797,770
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES
    CERTAIN SHARES
    o
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   25.22%
    12 TYPE OF REPORTING PERSON   CO

     

     2 
     

     

     Item 1.

     

    (a) Name of Issuer: Vaccitech plc

    (b) Address of Issuer's Principal Executive Offices: The Schrodinger Building, Heatley Road, The Oxford Science Park, Oxford OX4 4GE, United Kingdom

     

    Item 2.

     

    (a) Name of Person Filing: Oxford Science Enterprises plc

    (b) Address of Principal Business Office or, if none, Residence: 46 Woodstock Road, Oxford OX2 6HT, United Kingdom

    (c) Citizenship: England, United Kingdom

    (d) Title of Class of Securities: ADS, each representing one ordinary share

    (e) CUSIP Number: 91864C107

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not Applicable.

     

      (a) o A broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) o A bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) o An insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) o An investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).;
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
      (g) o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j) o A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J; and
      (k) o A group, in accordance with §240.13d–1(b)(1)(ii)(K). ). If a member of the group is filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:
     

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: 8,797,770

    (b) Percent of class: 25.22%

    (c) Number of shares as to which the person has:

    (i)     Sole power to vote or to direct the vote: 8,797,770

    (ii)    Shared power to vote or to direct the vote: 0

    (iii)   Sole power to dispose or to direct the disposition of: 8,797,770

    (iv)   Shared power to dispose or to direct the disposition of: 0

     

     3 
     

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not Applicable. 

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10. Certification

     

    Not Applicable.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 11, 2022

     

     

     

      Oxford Science Enterprises plc
         
         
         
      By:  /s/ Jim Wilkinson  
      Name: Jim Wilkinson  
      Title: Chief Financial Officer  

     

     

    4

     

     

     

    Get the next $VACC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VACC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VACC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Pelletier Nadege

    4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

    1/4/24 8:56:29 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Griffiths Graham

    4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

    1/4/24 8:55:03 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Enright William

    4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

    1/4/24 8:54:01 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VACC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

    New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its Phase 2 Hepatitis B trials of VTP-300 at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, November 10-14 in Boston, MA. The company also announced today that it has changed its name to Barinthus Biotherapeu

    11/6/23 9:05:56 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

    OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection and potential paths to a functional cure. Details are as follows: KOL Webinar: Seeking a Functional Cure for Chronic Hepatis BWednesday, September 20, 2023 between 14:00-15:00 ET.To register for the event

    9/13/23 8:00:00 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company's progress. "In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL," said Bill Enright, Vaccitech's Ch

    8/10/23 8:00:00 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VACC
    SEC Filings

    View All

    Vaccitech plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    1/5/24 4:15:12 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    12/22/23 4:01:12 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    11/9/23 4:32:00 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VACC
    Financials

    Live finance-specific insights

    View All

    Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company's progress. "In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL," said Bill Enright, Vaccitech's Ch

    8/10/23 8:00:00 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for the first quarter of 2023 and an overview of the Company's progress. "2023 has kicked off strongly for Vaccitech. In the first quarter, we strengthened our leadership team with the addition of Dr. Nadège Pelletier as our new Chief Scientific Officer, we generated positive final proof of concept data from one of o

    5/12/23 8:00:57 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

    OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for year end 2022 and an overview of the Company's progress. "2022 represented an extremely active year at Vaccitech in which the company continued to advance its exciting pipeline and strengthen the infrastructure necessary to support this and future growth. We announced the completion of enrollment of three clinical trials, and initiate

    3/24/23 8:06:29 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VACC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vaccitech plc (Amendment)

    SC 13G/A - Barinthus Biotherapeutics plc. (0001828185) (Subject)

    2/13/24 10:17:50 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vaccitech plc (Amendment)

    SC 13G/A - Vaccitech plc (0001828185) (Subject)

    1/20/23 1:35:01 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vaccitech plc

    SC 13G - Vaccitech plc (0001828185) (Subject)

    10/7/22 4:36:37 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care